Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease

Blood

Volumn 112, Issue 4, 2008, Pages 1357-1365

  Wahlstrom, Annika M ^a   Cutts, Briony A ^a   Liu, Meng ^a,b   Lindskog, Annika ^a   Karlsson, Christin ^a   Sjogren, Anna Karin M ^a   Andersson, Karin M E ^a   Young, Stephen G ^c   Bergo, Martin O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; K RAS PROTEIN; PROTEIN S ISOPRENYLCYSTEINE O METHYLTRANSFERASE; PROTEIN METHYLTRANSFERASE; PROTEIN P21; PROTEIN-S-ISOPRENYLCYSTEINE O-METHYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER GROWTH; CELL INFILTRATION; CONTROLLED STUDY; ENZYME INACTIVATION; ERYTHROID PRECURSOR CELL; FIBROBLAST; GENE MUTATION; HEMATOPOIETIC CELL; HISTOPATHOLOGY; LUNG TUMOR; MOUSE; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; SPLENOMEGALY; ANIMAL; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MYELOID CELLS; MYELOPROLIFERATIVE DISORDERS; PROTEIN METHYLTRANSFERASES; PROTO-ONCOGENE PROTEINS P21(RAS); SPLENOMEGALY;

EID: 51649099589     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-06-094060     Document Type: Article

References (29)

1. Rodenhuis S. ras and human tumors. Semin Cancer Biol. 1992;3:241-247.
2. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
3. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-665.
4. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144-148.
5. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185.
6. Young SG, Ambroziak P, Kim E, Clarke S. Postisoprenylation protein processing: CXXX (CaaX) endoproteases and isoprenylcysteine carboxyl methyltransferase. In: Tamanoi F, Sigman DS, eds. The Enzymes. Vol. 21. San Diego: Academic Press; 2000;155-213.
7. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1995;1:792-797.
8. Mahgoub N, Taylor BR, Gratiot M, et al. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 1999;94:2469-2476.
9. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459-14464.
10. Michaelson D, Ali W, Chiu VK, et al. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell. 2005;16:1606-1616.
11. Bergo MO, Gavino BJ, Hong C, et al. Inactivation of Icmt inhibits transformation by oncogenic K- Ras and B-Raf. J Clin Invest. 2004;113:539-550.
12. Donelson JL, Hodges HB, Macdougall DD, Henriksen BS, Hrycyna CA, Gibbs RA. Amide- substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltrans-ferase. Bioorg Med Chem Lett. 2006;16:4420-4423.
13. Anderson JL, Henriksen BS, Gibbs RA, Hrycyna CA. The isoprenoid substrate specificity of isoprenylcysteine carboxylmethyltransferase: development of novel inhibitors. J Biol Chem. 2005;280: 29454-29461.
14. Winter-Vann AM, Baron RA, Wong W, et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci USA. 2005;102:4336-4341.
15. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243-3248
16. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265-277.
17. Sjogren AK, Andersson KM, Liu M, et al. GG-Tase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest. 2007;117:1294-1304.
18. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101:597-602.
19. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113:528-538.
20. Wahlstrom AM, Cutts BA, Karlsson C, et al. Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease. Blood. 2007;109:763-768.
21. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004;5:375-387.
22. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269:1427-1429.
23. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of aconditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 2006;108:2041-2044.
24. Bergo MO, Leung GK, Ambroziak P, et al. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem. 2001;276:5841-5845.
25. Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM. Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood. 2003; 101:2250-2252.
26. Leung KF, Baron R, Ali BR, Magee AI, Seabra MC. Rab GTPases containing a CAAX motif are processed post-geranylgeranylation by proteolysis and methylation. J Biol Chem. 2007;282:1487-1497.
27. Seabra MC, Wasmeier C. Controlling the location and activation of Rab GTPases. Curr Opin Cell Biol. 2004;16:451-457.
28. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003;4:111-120.
29. Van Meter ME, Diaz-Flores E, Archard JA, et al. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood. 2007;109:3945-3952.